Panniculitis Associated with Severe α1-Antitrypsin Deficiency: Treatment and Review of the Literature

Archives of Dermatology

Volumn 123, Issue 12, 1987, Pages 1655-1661

  Smith, Kevin C ^a   Pittelkow, Mark R ^a   Su, W P Daniel ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; DAPSONE; PREDNISONE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CASE REPORT; HUMAN; PANNICULITIS; REVIEW; SHORT SURVEY; SKIN ULCER; THERAPY;

ADIPOSE TISSUE; ADULT; AGED; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; BIOPSY; BLOOD PROTEINS; CASE REPORT; DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; HUMAN; PANNICULITIS, NODULAR NONSUPPURATIVE; PHENOTYPE; PREDNISONE; PROTEASE INHIBITORS; RECURRENCE;

EID: 0023485295     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1987.01660360083017     Document Type: Article

References (81)

1. Rubinstein HM, Jaffer AM, Kudrna JC, et al: Alpha-1-antitrypsin deficiency with severe panniculitis. Ann Intern Med 1977;86:742–744.
2. Bleumink E, Klokke AH: Relationship between Weber-Christian panniculitis and the ZZ phenotype of alpha-1-antitrypsin. Arch Dermatol Res 1985;277:328–329.
3. Bleumink E, Klokke HA: Protease-inhibitor deficiencies in a patient with Weber-Christian panniculitis. Arch Dermatol 1984;120:936–940.
4. Pottage JC Jr, Trenholme GM, Aronson IK, et al: Panniculitis associated with histoplasmosis and alpha-1-antitrypsin deficiency. Am J Med 1983;75:150–153.
5. Clark P, Breit SN, Dawkins RL, et al: Genetic study of a family with two members with Weber Christian disease (panniculitis) and alpha-1-antitrypsin deficiency. Am J Med Genet 1982; 13:57–62.
6. Lonchampt F, Blanc D, Terrasse F, et al: Maladie de WeberChristian associée à un déficit familial en alpha-I-antitrypsine. Ann Dermatol Venereol 1985;112:35–39.
7. Breit SN, Clark P, Robinson JP, et al: Familial occurrence of alpha-1-antitrypsin deficiency and Weber-Christian disease. Arch Dermatol 1983;119:198–202.
8. Warter J, Storck D, Grosshans E, et al: Syndrome de Weber-Christian associé à un déficit en alpha-I-antitrypsine: Enquête familiale. Ann Med Interne 1972;123:877–882.
9. Olmos L, Superby A, Lueiro M: Deficiencia de alfa-1-antitripsina en la paniculitis de Weber-Christian, abstracted. Actas Dermato-sifilograficas 1981;72:371–376.
10. Balk E, Bronsveld W, Van der Deyl JA, et al: Alpha-1-antitrypsin deficiency with vascular leakage syndrome and panniculitis. Neth J Med 1982;25:138–141.
11. Guilmot J-L, Lamisse F, Choutet P, et al: Maladie de Weber-Christian associeé à un déficit en alpha-1-antitrypsine. Presse Med 1980;9:886.
12. Grosshans E, Warter J, Storck D, et al: A propos d'une panniculite liquéfiante: Les manifestations cutanées des déficits en alpha-I-antitrypsine. Bull Soc Fr Dermatol Syphiligr 1973;80:244–247.
13. Viraben R, Massip P, Dicostanzo B, et al: Necrotic panniculitis with alpha-1-antitrypsin deficiency. J Am Acad Dermatol 1986;14:684–687.
14. Miller RAW, cited by Ross JB: Atlantic Provinces Dermatology Association Society meeting, May 3, 1986. J Can Dermatol Assoc 1986;1:13–17.
15. Su WPD, Smith KC, Pittelkow MR, et al: Alpha-1-antitrypsin deficiency panniculitis: A histopathologic and immunopathologic study of four cases. Am J Dermatopathol, in press.
16. Wewers MD, Casolaro MA, Sellers SE, et al: Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987;316:1055–1062.
17. Travis J, Matheson NR, Johnson D, et al: Human alphaproteinase inhibitor and human alpha-antichymotrypsin: Properties and mechanism studies, in Bing DH (ed): Chemistry and Biology of Plasma Proteins. Elmsford, NY, Pergamon Press Inc, 1979, pp 343–352.
18. Schmidt W, Havemann K: Isolation of elastase-like and chymotrypsin-like neutral proteases from human granulocytes. Hoppe-Seylers Z Physiol Chem 1974;355:1077–1082.
19. Breit SN, Penny R: The role of alpha-1-protease inhibitor (alpha-1-antitrypsin) in the regulation of immunologic and inflammatory reactions. Aust NZ J Med 1980;10:449–453.
20. Janoff A: Neutrophil proteases in inflammation. Annu Rev Med 1972;23:177–190.
21. Morse JO: Alpha-1-antitrypsin deficiency: Parts I and II. N Engl J Med 1978;299:1045-1048; 1099–1105.
22. Cox DW, Johnson AM, Fagerhol MK: Report of nomenclature meeting for alpha-1-antitrypsin. Hum Genet 1980;53:429–433.
23. Norum RA, Bearn AG, Briscoe WA, et al: Alpha-1-antitrypsin and disease. Mt Sinai J Med 1977;44:821–827.
24. Yoshida A, Lieberman J, Gaidulis L, et al: Molecular abnormality of human alpha-1-antitrypsin variant (Pi-ZZ) associated with plasma activity deficiency. Proc Nati Acad Sci USA 1976;73:1324–1328.
25. Kueppers F, Black LF: Alpha-antitrypsin and its deficiency. Am Rev Respir Dis 1974;110:176–194.
26. Garver RI, Jr, Mornex JF, Nukiwa T, et al: Alpha-1-antitrypsin deficiency and emphysema caused by homozygous inheritance of non-expressing alpha-1-antitrypsin genes. N Engl J Med 1986;314:762–766.
27. Sveger T: Liver disease in alpha-1-antitrypsin deficiency detected by screening of 200 000 infants. N Engl J Med 1976; 294:1316–1321.
28. Eriksson S, Carlson J, Velez R: Risk of cirrhosis and primary liver cancer in alpha-1-antitrypsin deficiency. N Engl J Med 1986;314:736–739.
29. Sharp HL, Bridges RA, Krivit W, et al: Cirrhosis associated with alpha-1-antitrypsin deficiency: A previously unrecognized inherited disorder. J Lab Clin Med 1969;73:934–939.
30. Eriksson S, Moestrup T, Hägerstrand I: Liver, lung and malignant disease in heterozygous (Pi MZ) alpha-1-antitrypsin deficiency. Acta Med Scand 1975;198:243–247.
31. Brandrup F, Østergaard PA: Alpha-1-antitrypsin deficiency associated with persistent cutaneous vasculitis: Occurrence in a child with liver disease. Arch Dermatol 1978;114:921–924.
32. Doeglas HMG, Klasen EC, Bleumink E: Alpha-1-antitrypsin deficiency and PI typing in patients with chronic urticaria. Br J Dermatol 1985;112:381–385.
33. Heng MCY, Moy RL, Lieberman J: Alpha-1-antitrypsin deficiency in severe psoriasis. Br J Dermatol 1985;112:129–133.
34. Lipkin G, Galdston M, Kueppers F: Alpha-1-antitrypsin deficiency genes: Contributory defect in a subset of psoriatics? J Am Acad Dermatol 1984;11:615–619.
35. Beckman G, Beckman L, Lidén S: Association between psoriasis and the alpha-1-antitrypsin deficiency gene Z. Acta Derm Venereol 1980;60:163–164.
36. Bleumink E, Doeglas HMG: Protease inhibitor deficiencies in a patient with angio-oedema: Results of family studies. Br J Dermatol 1980;102:473–474.
37. Crovato F, Rebora A: Alpha-1-antitrypsin deficiency. Arch Dermatol 1977;113:236.
38. Breit SN, Wakefield D, Robinson JP, et al: The role of alpha-1-antitrypsin deficiency in the pathogenesis of immune disorders. Clin Immunol Immunopathol 1985;35:363–380.
39. Fulton RJ, Hart DA: Detection and partial characterization of lymphoid cell surface proteases. Cell Immunol 1980;55:394–405.
40. Arora PK, Miller HC, Aronson LD: Alpha-1-antitrypsin is an effector of immunological stasis. Nature 1978;274:589–590.
41. Bata J, Deviller P, Colobert L: Inhibition de la biosynthèse du DNA chez les lymphocytes humains par l'effet de l'alpha-1-antitrypsine, abstracted. C R Acad Sci 1977;285:1499–1501.
42. Vischer TL: Protease inhibitors reduce mitogen induced lymphocyte stimulation. Immunology 1979;36:811–813.
43. Kitagawa S, Takaku F, Sakamoto S: Serine protease inhibitors inhibit superoxide production by human polymorphonuclear leukocytes and monocytes stimulated by various surface active agents. FEBS Lett 1979;107:331–334.
44. Nagai K, Nakamura T, Koyama J: Characterization of macrophage proteases involved in the ingestion of antigenantibody complexes by the use of protease inhibitors. FEBS Lett 1978;92:299–302.
45. Goldstein BD, Witz G, Amoruso M, et al: Protease inhibitors antagonize the activation of polymorphonuclear leukocyte oxygen consumption. Biochem Biophys Res Commun 1979;88:854–860.
46. Kitagawa S, Takaku F, Sakamoto S: Evidence that proteases are involved in superoxide production by human polymorphonuclear leukocytes and monocytes. J Clin Invest 1980;65:74–81.
47. Musson RA, Becker EL: The role of an activatable esterase in immune-dependent phagocytosis by human neutrophils. J Immunol 1977;118:1354–1365.
48. Plewig G, Schöpf E: Anti-inflammatory effects of antimicrobial agents. J Invest Dermatol 1975;65:532–536.
49. Esterly NB, Furey NL, Flanagan LE: The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978;70:51–55.
50. Stendahl O, Molin L, Dahlgren C: The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone: A possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest 1978;62:214–220.
51. Robert L, Bellon G, Hornebeck W: Characterization of different elastases: Their possible role in the genesis of emphysema. Bull Eur Physiopathol Respir 1980;16(suppl):199–206.
52. Claire M, Jacotot B, Robert L: Characterization of lipids associated with macromolecules of the intercellular matrix of human aorta. Connect Tissue Res 1976;4:61–71.
53. Jacotot B, Beaumont JL, Monnier G, et al: Role of elastic tissue in cholesterol deposition in the arterial wall. Nutr Metab 1973;15:46–58.
54. Goetzl EJ: Modulation of human neutrophil polymorphonuclear leucocyte migration by human plasma alpha-globulin inhibitors and synthetic esterase inhibitors. Immunology 1975;29:163–174.
55. Dierich MP, Landen B, Schmitt M: Complement receptor analogous factors in human serum: I. Isolation of a molecule inhibitory for complement dependent rosette formation, its identification as alpha-1-antitrypsin and its functional characterization. Immunobiology 1979;156:153–167.
56. Benitez-Bribiesca L, Freyre-Horta R: Immunofluorescent localization of alpha-1-antitrypsin in human polymorphonuclear leukocytes. Life Sci 1978;22:99–104.
57. Cohen AB: Interrelationships between the human alveolar macrophage and alpha-1-antitrypsin. J Clin Invest 1973;52:2793–2799.
58. Ray MB, Desmet VJ: Immunohistochemical demonstration of alpha-1-antitrypsin in the islet cells of human pancreas. Cell Tissue Res 1978;187:69–77.
59. Benítez-Bribiesca L, Freyre R, De la Vega G: Alpha-1-antitrypsin in human mast cells: Immunofluorescent localization. Life Sci 1973;13:631–638.
60. Henson PM: The immunologic release of constituents from neutrophil leukocytes: I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles. J Immunol 1971;107:1535–1546.
61. Janoff A, Carp H, Lee DK: Inactivation of alpha-1-proteinase inhibitor and bronchial mucous proteinase inhibitor by cigarette smoke in vitro and in vivo. Bull Eur Physiopathol Respir 1980;16(suppl):321–338.
62. Travis J, Beatty K, Wong PS, et al: Oxidation of alpha-1-proteinase inhibitor as a major, contributing factor in the development of pulmonary emphysema. Bull Eur Physiopathol Respir 1980;16(suppl):341–351.
63. Shechter Y, Burstein Y, Gertler A: Effect of oxidation of methionine residues in chicken ovoinhibitor on its inhibitory activities against trypsin, chymotrypsin, and elastase. Biochemistry 1977;16:992–997.
64. Johnson D, Travis J: Structural evidence for methionine at the reactive site of human alpha-1-proteinase inhibitor. J Biol Chem 1978;253:7142–7144.
65. Johnson D, Travis J: The oxidative inactivation of human alpha-1-proteinase inhibitor: Further evidence for methionine at the reactive center. J Biol Chem 1979;254:4022–4026.
66. Lang PG Jr: Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol 1979;1:479–492.
67. Edelson PJ, Cohn ZA: Peroxidase-mediated mammalian cell cytotoxicity. J Exp Med 1973;138:318–323.
68. Clark RA, Klebanoff SJ, Einstein AB, et al: PeroxidaseH2O2-halide system: Cytotoxic effect on mammalian tumor cells. Blood 1975;45:161–170.
69. Clark RA, Klebanoff SJ: Neutrophil-mediated tumor cell cytotoxicity: Role of the peroxidase system. J Exp Med 1975; 141:1442–1447.
70. Cohen AB: Unraveling the mysteries of alpha-1-antitrypsin deficiency. N Engl J Med 1986;314:778–779.
71. Gadek JE, Klein HG, Holland PV, et al: Replacement therapy in hereditary emphysema: Reestablishment of proteaseantiprotease balance within the lung, abstracted. Clin Res 1980;28:528.
72. Gadek JE, Klein HG, Holland PV, et al: Replacement therapy of alpha-1-antitrypsin deficiency: Reversal of proteaseantiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981;68:1158–1165.
73. Gadek JE, Crystal RG: Experience with replacement therapy in the destructive lung disease associated with severe alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1983;127(suppl):45–46.
74. Madanes AE, Farber M: Danazol. Ann Intern Med 1982; 96:625–630.
75. Gadek JE, Fulmer JD, Gelfand JA, et al: Danazol-induced augmentation of serum alpha-1-antitrypsin levels in individuals with marked deficiency of this antiprotease. J Clin Invest 1980; 66:82–87.
76. Gee JBL, Stevens CA, Hinman LM: Elastase and lysozyme secretion by peritoneal macrophages: Effects of dexamethasone and rifampin. Bull Eur Physiopathol Respir 1980;16(Suppl):415–421.
77. Buss WC, Morgan R, Guttmann J, et al: Rifampicin inhibition of protein synthesis in mammalian cells. Science 1978; 200:432–434.
78. Janoff A, Dearing R: Prevention of elastase-induced experimental emphysema by a synthetic elastase inhibitor administered orally. Bull Eur Physiopathol Respir 1980;16(suppl):399–405.
79. Powers JC, Gupton BF, Harley AD, et al: Specificity of porcine pancreatic elastase, human leukocyte elastase and cathepsin G: Inhibition with peptide chloromethyl ketones. Biochim Biophys Acta 1977;485:156–166.
80. Katz SI, Gallin JI, Hertz KC, et al: Erythema elevatum diutinum: Skin and systemic manifestations, immunologic studies, and successful treatment with dapsone. Medicine 1977;56:443–455.
81. King LE Jr, Rees RS: Dapsone treatment of a brown recluse bite. JAMA 1983;250:648.